About this trial
Insomnia is defined as the inability to fall asleep or stay asleep at night and it is one of the most prevalent sleep disorders that can have deleterious impacts on health and this population's quality of life. Currently, both pharmaceutical interventions (trazodone) and cognitive behavioral therapy (CBTi) are widely used to treat patients with insomnia. Although CBTi has been efficacious in many patients, multitude of barriers for receiving treatment such as its limited availability of therapists, high costs and long wait times challenge its ability in sufficiently meeting the population's health needs and demands. To improve the delivery of CBT, electronically delivered CBTi (e-CBTi) has been developed as an accessible and effective alternative intervention for improving sleep outcomes in patients with insomnia. While evidence suggest that e-CBTi is effective when compared to placebos/waitlist control, evidence comparing guided e-CBTi to pharmaceutical interventions is still insufficient and needs further exploration.
Eligibility criteria
Qualifiers
At least 18 years of age at the start of the study
Non-organic insomnia
Difficulty initiating, and/or maintaining sleep for ≥ 30 minutes and
Use of sleep-promoting medication at least three nights per week for at least 3 months
Disqualifiers
Presence of another untreated sleep disorder
Alcohol or substance use disorder
Ongoing CBT
Non-assessed or untreated clinically significant somatic or mental symptoms or illnesses
Trial design
Treatments tested in this trial
- e-CBTi
- Trazodone
Treatment groups
Sponsors and collaborators
Dr. Nazanin Alavi
Lead sponsor
Queen's University
Sponsor institution
Online PsychoTherapy Clinic
Collaborator